O-1602– synthetic cannabidiol analog, GPR-18 & GPR-55 agonist

 

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2                                                                    (full – 2010)  http://pharmrev.aspetjournals.org/content/62/4/588.full.pdf+html

 

A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. (full – 2011)                                        http://joe.endocrinology-journals.org/content/211/2/177.long

 

A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents.        (abst – 2011)                           http://www.ncbi.nlm.nih.gov/pubmed/21726355

 

The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55.                                                           (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/21683763

 

A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents.        (abst – 2011)                           http://www.ncbi.nlm.nih.gov/pubmed/21726355

 

The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.                                                           (abst – 2011)        http://www.ncbi.nlm.nih.gov/pubmed/21744421

 

The atypical cannabinoid O-1602 shows antitumorigenic effects in colon cancer cells and reduces tumor growth in a colitis-associated colon cancer model                                                                    (full – 2012)  http://www.biomedcentral.com/content/pdf/2050-6511-13-S1-A23.pdf

 

GPR18 in microglia: implications for the CNS and endocannabinoid system signaling (full – 2012)                                          http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02019.x/full

 

siRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migration                                                       (full – 2012)  http://www.jmolecularsignaling.com/content/7/1/10

 

The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. (abst – 2012)                                            http://www.ncbi.nlm.nih.gov/pubmed/21981246

 

The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain.                                                                   (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22227298

 

Evidence for the Putative Cannabinoid Receptor (GPR55)-Mediated Inhibitory Effects on Intestinal Contractility in Mice.                                                             (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/22759743

 

The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System. (abst – 2012)                                           http://www.ncbi.nlm.nih.gov/pubmed/22831390

 

N- 02, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms     (abst – 2012)  http://link.springer.com/article/10.1007%2Fs00109-012-0957-1

Share a link for